[1]
Whelan TJ, Aldrich JE, Voruganti SM, Wong OS, Filbee JF, Joseph PJ, Jeffrey JF. A comparison of manual and remote afterloading in the treatment of carcinoma of the cervix: increasing dose rate with a flexible applicator. Clinical oncology (Royal College of Radiologists (Great Britain)). 1992 Sep:4(5):294-8
[PubMed PMID: 1390345]
[2]
Seneviratne D, McLaughlin C, Todor D, Kaplan B, Fields EC. The CivaSheet: The new frontier of intraoperative radiation therapy or a pricier alternative to LDR brachytherapy? Advances in radiation oncology. 2018 Jan-Mar:3(1):87-91. doi: 10.1016/j.adro.2017.10.005. Epub 2017 Oct 20
[PubMed PMID: 29556586]
Level 3 (low-level) evidence
[3]
Dimopoulos JC, Petrow P, Tanderup K, Petric P, Berger D, Kirisits C, Pedersen EM, van Limbergen E, Haie-Meder C, Pötter R. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2012 Apr:103(1):113-22. doi: 10.1016/j.radonc.2011.12.024. Epub 2012 Jan 30
[PubMed PMID: 22296748]
Level 2 (mid-level) evidence
[4]
Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, Butler WM, Grimm PD, Stone NN, Potters L, Zietman AL, Zelefsky MJ, American Brachytherapy Society. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012 Jan-Feb:11(1):6-19. doi: 10.1016/j.brachy.2011.07.005. Epub
[PubMed PMID: 22265434]
Level 3 (low-level) evidence
[5]
Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, Ramirez PT, Frumovitz M, Bodurka DC, Sood AK. Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer. 2010 Feb 1:116(3):625-30. doi: 10.1002/cncr.24811. Epub
[PubMed PMID: 20052724]
[6]
Viswanathan AN, Beriwal S, De Los Santos JF, Demanes DJ, Gaffney D, Hansen J, Jones E, Kirisits C, Thomadsen B, Erickson B, American Brachytherapy Society. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy. 2012 Jan-Feb:11(1):47-52. doi: 10.1016/j.brachy.2011.07.002. Epub
[PubMed PMID: 22265437]
Level 3 (low-level) evidence
[7]
Pötter R, Tanderup K, Schmid MP, Jürgenliemk-Schulz I, Haie-Meder C, Fokdal LU, Sturdza AE, Hoskin P, Mahantshetty U, Segedin B, Bruheim K, Huang F, Rai B, Cooper R, van der Steen-Banasik E, Van Limbergen E, Pieters BR, Tan LT, Nout RA, De Leeuw AAC, Ristl R, Petric P, Nesvacil N, Kirchheiner K, Kirisits C, Lindegaard JC, EMBRACE Collaborative Group. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. The Lancet. Oncology. 2021 Apr:22(4):538-547. doi: 10.1016/S1470-2045(20)30753-1. Epub
[PubMed PMID: 33794207]
[8]
Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG, Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecologic oncology. 2004 Mar:92(3):744-51
[PubMed PMID: 14984936]
[9]
Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet (London, England). 2000 Apr 22:355(9213):1404-11
[PubMed PMID: 10791524]
Level 1 (high-level) evidence
[10]
Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit VTHBM, Nout RA, PORTEC Study Group. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. British journal of cancer. 2018 Oct:119(9):1067-1074. doi: 10.1038/s41416-018-0310-8. Epub 2018 Oct 25
[PubMed PMID: 30356126]
[11]
Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Diver E, Fisher CM, Frederick P, Gaffney DK, George S, Giuntoli R, Han E, Howitt B, Huh WK, Lea J, Mariani A, Mutch D, Nekhlyudov L, Podoll M, Remmenga SW, Reynolds RK, Salani R, Sisodia R, Soliman P, Tanner E, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Motter AD. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. Journal of the National Comprehensive Cancer Network : JNCCN. 2021 Aug 1:19(8):888-895. doi: 10.6004/jnccn.2021.0038. Epub 2021 Aug 1
[PubMed PMID: 34416706]
[12]
Small W Jr, Beriwal S, Demanes DJ, Dusenbery KE, Eifel P, Erickson B, Jones E, Rownd JJ, De Los Santos JF, Viswanathan AN, Gaffney D, American Brachytherapy Society. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy. 2012 Jan-Feb:11(1):58-67. doi: 10.1016/j.brachy.2011.08.005. Epub
[PubMed PMID: 22265439]
Level 3 (low-level) evidence
[13]
Coon D, Beriwal S, Heron DE, Kelley JL, Edwards RP, Sukumvanich P, Zorn KK, Krivak TC. High-dose-rate Rotte "Y" applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results. International journal of radiation oncology, biology, physics. 2008 Jul 1:71(3):779-83. doi: 10.1016/j.ijrobp.2007.10.026. Epub 2008 Feb 6
[PubMed PMID: 18258388]
[14]
Nag S, Erickson B, Parikh S, Gupta N, Varia M, Glasgow G. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. International journal of radiation oncology, biology, physics. 2000 Oct 1:48(3):779-90
[PubMed PMID: 11020575]
[15]
. NSABP B-39, RTOG 0413: A Randomized Phase III Study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical advances in hematology & oncology : H&O. 2006 Oct:4(10):719-21
[PubMed PMID: 17111558]
Level 3 (low-level) evidence
[16]
Shah C, Vicini F, Shaitelman SF, Hepel J, Keisch M, Arthur D, Khan AJ, Kuske R, Patel R, Wazer DE. The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation. Brachytherapy. 2018 Jan-Feb:17(1):154-170. doi: 10.1016/j.brachy.2017.09.004. Epub 2017 Oct 23
[PubMed PMID: 29074088]
Level 3 (low-level) evidence
[17]
Yamada Y, Rogers L, Demanes DJ, Morton G, Prestidge BR, Pouliot J, Cohen GN, Zaider M, Ghilezan M, Hsu IC, American Brachytherapy Society. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy. 2012 Jan-Feb:11(1):20-32. doi: 10.1016/j.brachy.2011.09.008. Epub
[PubMed PMID: 22265435]
Level 3 (low-level) evidence
[18]
Morton G, McGuffin M, Chung HT, Tseng CL, Helou J, Ravi A, Cheung P, Szumacher E, Liu S, Chu W, Zhang L, Mamedov A, Loblaw A. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2020 May:146():90-96. doi: 10.1016/j.radonc.2020.02.009. Epub 2020 Mar 5
[PubMed PMID: 32146259]
Level 1 (high-level) evidence
[19]
Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. International journal of radiation oncology, biology, physics. 2017 Jun 1:98(2):275-285. doi: 10.1016/j.ijrobp.2016.11.026. Epub 2016 Nov 24
[PubMed PMID: 28262473]
Level 1 (high-level) evidence
[20]
Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. International journal of radiation oncology, biology, physics. 2017 Jun 1:98(2):286-295. doi: 10.1016/j.ijrobp.2017.01.008. Epub 2017 Jan 6
[PubMed PMID: 28433432]
Level 1 (high-level) evidence
[21]
Crook JM, Jezioranski J, Grimard L, Esche B, Pond G. Penile brachytherapy: results for 49 patients. International journal of radiation oncology, biology, physics. 2005 Jun 1:62(2):460-7
[PubMed PMID: 15890588]
[22]
Milosevic MF, Warde PR, Banerjee D, Gospodarowicz MK, McLean M, Catton PA, Catton CN. Urethral carcinoma in women: results of treatment with primary radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2000 Jul:56(1):29-35
[PubMed PMID: 10869752]
[23]
Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Archives of ophthalmology (Chicago, Ill. : 1960). 2006 Dec:124(12):1684-93
[PubMed PMID: 17159027]
Level 1 (high-level) evidence
[24]
American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address: paulfinger@eyecancer.com, ABS – OOTF Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014 Jan-Feb:13(1):1-14. doi: 10.1016/j.brachy.2013.11.008. Epub 2013 Dec 24
[PubMed PMID: 24373763]
Level 3 (low-level) evidence
[25]
Jiang P, Purtskhvanidze K, Kandzia G, Neumann D, Luetzen U, Siebert FA, Roider J, Dunst J. (106)Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma. Radiation oncology (London, England). 2020 Jul 29:15(1):183. doi: 10.1186/s13014-020-01621-4. Epub 2020 Jul 29
[PubMed PMID: 32727533]
[26]
Filì M, Trocme E, Bergman L, See TRO, André H, Bartuma K, Girnita L, All-Eriksson C, Seregard S, Stålhammar G. Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm. The British journal of ophthalmology. 2020 Jan:104(1):26-32. doi: 10.1136/bjophthalmol-2018-313419. Epub 2019 Mar 25
[PubMed PMID: 30910871]
[27]
Shields CL, Mashayekhi A, Sun H, Uysal Y, Friere J, Komarnicky L, Shields JA. Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. Ophthalmology. 2006 Nov:113(11):2087-92
[PubMed PMID: 16949158]
[28]
Gabayan AJ, Green SB, Sanan A, Jenrette J, Schultz C, Papagikos M, Tatter SP, Patel A, Amin P, Lustig R, Bastin KT, Watson G, Burri S, Stea B. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery. 2006 Apr:58(4):701-9; discussion 701-9
[PubMed PMID: 16575334]
Level 2 (mid-level) evidence
[29]
Welsh J, Sanan A, Gabayan AJ, Green SB, Lustig R, Burri S, Kwong E, Stea B. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. International journal of radiation oncology, biology, physics. 2007 May 1:68(1):159-65
[PubMed PMID: 17331666]
Level 2 (mid-level) evidence
[30]
Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, Malkin MG, Mealey JJ Jr, Neal JH, Olson J, Robertson JT, Barnett GH, Bloomfield S, Albright R, Hochberg FH, Hiesiger E, Green S, Brain Tumor Cooperative Group. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery. 2002 Aug:51(2):343-55; discussion 355-7
[PubMed PMID: 12182772]
Level 1 (high-level) evidence
[31]
Gessler DJ, Ferreira C, Dusenbery K, Chen CC. GammaTile(®): Surgically targeted radiation therapy for glioblastomas. Future oncology (London, England). 2020 Oct:16(30):2445-2455. doi: 10.2217/fon-2020-0558. Epub 2020 Jul 3
[PubMed PMID: 32618209]
[32]
Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. Journal of the National Cancer Institute. 2011 Dec 7:103(23):1761-70. doi: 10.1093/jnci/djr432. Epub 2011 Nov 4
[PubMed PMID: 22056739]
Level 2 (mid-level) evidence
[33]
Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. The Lancet. Oncology. 2012 Feb:13(2):163-71. doi: 10.1016/S1470-2045(11)70320-5. Epub 2011 Dec 7
[PubMed PMID: 22154591]
Level 1 (high-level) evidence
[34]
Levendag PC, Peters R, Meeuwis CA, Visch LL, Sipkema D, de Pan C, Schmitz PI. A new applicator design for endocavitary brachytherapy of cancer in the nasopharynx. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1997 Oct:45(1):95-8
[PubMed PMID: 9364638]
[35]
Lin Y, Ouyang Y, Lu Z, Liu Y, Chen K, Cao X. Long-Term Outcomes of Three-Dimensional High-Dose-Rate Brachytherapy for Locally Recurrent Early T-Stage Nasopharyngeal Carcinoma. Frontiers in oncology. 2019:9():278. doi: 10.3389/fonc.2019.00278. Epub 2019 Apr 26
[PubMed PMID: 31134143]
[36]
Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D, Birkeland AC, Brizel DM, Busse PM, Cmelak AJ, Colevas AD, Eisele DW, Galloway T, Geiger JL, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Mell LK, Mittal BB, Pinto HA, Rocco JW, Rodriguez CP, Savvides PS, Schwartz D, Shah JP, Sher D, St John M, Weber RS, Weinstein G, Worden F, Yang Bruce J, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. Journal of the National Comprehensive Cancer Network : JNCCN. 2022 Mar:20(3):224-234. doi: 10.6004/jnccn.2022.0016. Epub
[PubMed PMID: 35276673]
[37]
Wendt CD, Peters LJ, Delclos L, Ang KK, Morrison WH, Maor MH, Robbins KT, Byers RM, Carlson LS, Oswald MJ. Primary radiotherapy in the treatment of stage I and II oral tongue cancers: importance of the proportion of therapy delivered with interstitial therapy. International journal of radiation oncology, biology, physics. 1990 Jun:18(6):1287-92
[PubMed PMID: 2370178]
[38]
Campbell SR, Shah C, Scott JG, Mesko N, Nystrom L, Kolar M, Largo AC, Kamrava M, Mourtada F, Naghavi AO, Harrison LB. American Brachytherapy Society (ABS) consensus statement for soft-tissue sarcoma brachytherapy. Brachytherapy. 2021 Nov-Dec:20(6):1200-1218. doi: 10.1016/j.brachy.2021.05.011. Epub 2021 Jul 21
[PubMed PMID: 34303600]
Level 3 (low-level) evidence
[39]
Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Mar:14(3):859-68
[PubMed PMID: 8622034]
Level 1 (high-level) evidence
[40]
Schmults CD, Blitzblau R, Aasi SZ, Alam M, Andersen JS, Baumann BC, Bordeaux J, Chen PL, Chin R, Contreras CM, DiMaio D, Donigan JM, Farma JM, Ghosh K, Grekin RC, Harms K, Ho AL, Holder A, Lukens JN, Medina T, Nehal KS, Nghiem P, Park S, Patel T, Puzanov I, Scott J, Sekulic A, Shaha AR, Srivastava D, Stebbins W, Thomas V, Xu YG, McCullough B, Dwyer MA, Nguyen MQ. NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022. Journal of the National Comprehensive Cancer Network : JNCCN. 2021 Dec:19(12):1382-1394. doi: 10.6004/jnccn.2021.0059. Epub
[PubMed PMID: 34902824]
[41]
Guinot JL, Rembielak A, Perez-Calatayud J, Rodríguez-Villalba S, Skowronek J, Tagliaferri L, Guix B, Gonzalez-Perez V, Valentini V, Kovacs G, GEC ESTRO. GEC-ESTRO ACROP recommendations in skin brachytherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018 Mar:126(3):377-385. doi: 10.1016/j.radonc.2018.01.013. Epub 2018 Feb 16
[PubMed PMID: 29455924]
[42]
Skowronek J. Brachytherapy in the treatment of skin cancer: an overview. Postepy dermatologii i alergologii. 2015 Oct:32(5):362-7. doi: 10.5114/pdia.2015.54746. Epub 2015 Oct 29
[PubMed PMID: 26759545]
Level 3 (low-level) evidence
[43]
Watson M, Holman DM, Maguire-Eisen M. Ultraviolet Radiation Exposure and Its Impact on Skin Cancer Risk. Seminars in oncology nursing. 2016 Aug:32(3):241-54. doi: 10.1016/j.soncn.2016.05.005. Epub 2016 Jul 29
[PubMed PMID: 27539279]